Skip to main content
. 2014 Nov 21;7:679–687. doi: 10.2147/JPR.S70200

Figure 3.

Figure 3

Mean changes from pre-milnacipran exposure in VAS pain scores.

Notes: The group with ≥50% pain reduction at randomization represents the protocol-defined responder population of the randomized withdrawal study; *P<0.05 versus milnacipran; **P<0.01; ***P<0.001.

Abbreviations: MLN, milnacipran; VAS, visual analog scale.